Big PharmaAtlas

Evidence

4 cited sources · both-sides readings on each item

• BMJ piece on pharmaceutical influence and regulation

  The BMJ · secondary

  • Pos A · Read as critical secondary analysis that still assumes reformable public regulators.“pharmaceutical industry”
  • Pos B · Read as arguing industry influence systematically shapes regulatory environments.“pharmaceutical industry”
  • Pos A · Read as raising conflicts that stronger firewalls inside fee systems could address.“conflicts of interest”
  • Pos B · Read as treating funding and access patterns as central to independence debates.“conflicts of interest”
• FDA PDUFA overview

  U.S. Food and Drug Administration · primary

  • Pos A · Read as showing fee programs are statutory public tools with published goals.“user fee”
  • Pos B · Read as showing durable industry fee dependence inside drug review.“user fee”
  • Pos A · Read as centering process metrics rather than outsourcing approval decisions.“PDUFA”
  • Pos B · Read as documenting recurring reauthorization architecture with industry at the table.“PDUFA”
• EMA funding governance

  European Medicines Agency · primary

  • Pos A · Read as a comparative public funding disclosure consistent with managed-fee models.“funding”
  • Pos B · Read as showing fee dependence is multi-jurisdictional, not a one-agency quirk.“funding”
  • Pos A · Read as evidence that fee transparency can coexist with public-interest mandates.“governance”
  • Pos B · Read as evidence that similar fee structures attract similar independence critiques.“governance”
• GAO review touching FDA capacity/oversight

  U.S. Government Accountability Office · primary

  • Pos A · Read as evidence of external audit scrutiny of FDA performance.“Food and Drug Administration”
  • Pos B · Read as evidence of capacity pressures that can amplify industry agenda-setting.“Food and Drug Administration”
  • Pos A · Read as compatible with fees as overseen capacity support.“oversight”
  • Pos B · Read as compatible with funding structure shaping practical independence.“oversight”